BioCentury
ARTICLE | Company News

Magainin IL-9 deal with Genentech

May 1, 2000 7:00 AM UTC

The companies will co-develop an anti-IL-9 antibody to treat asthma, with options to include other respiratory disease therapeutics. The collaboration will combine DNA's antibody development expertise with MAGN's genetic identification of IL-9 as a mediator of asthma. The deal follows the completion of a 1998 collaboration between the companies to evaluate whether a blocking antibody to IL-9 suppresses the asthmatic response (see BioCentury, Jan. 11, 1999). ...